Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ranibizumab + verteporfin
- Development stage
- Phase 4
- Lead developer
- Novartis
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Ophthalmic, Intravenous
01
Overview
A combination therapy consisting of the anti-VEGF monoclonal antibody fragment ranibizumab and the photosensitizer verteporfin, used in conjunction with photodynamic therapy (PDT). This regimen is designed to treat neovascular age-related macular degeneration (nAMD) by targeting multiple pathways: ranibizumab inhibits vascular endothelial growth factor A (VEGF-A) to reduce vascular permeability and angiogenesis, while verteporfin PDT causes selective vascular occlusion of existing choroidal neovascular membranes. The Fondazione G.B. Bietti, IRCCS evaluated this combination in the Phase 2 LUVI study to determine if the dual approach improves visual outcomes or reduces the treatment burden compared to monotherapy.
- Other names
- Lucentis and Visudyne CombinationLUVI combination
02
Targets
Beyond the preview
Go deeper on ranibizumab + verteporfin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ranibizumab + verteporfin.